USMAN SIDDIQUI

Allopathic & Osteopathic Physicians|Hospitalist NYACK, NY NPI 1356774491

General Payments — all program years on this page

$42,763.40

  • Category: General Payments
  • Program years: PY2020–2024
  • Record count: 33
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $20,386.49 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Abbott Laboratories $20,364.6815
Novo Nordisk AS $21.811

By program year

Program yearAmountRecords
2020 $5,863.807
2021 $12.311
2022 $1,530.001
2023 $14,970.808
2024 $20,386.4916

Records — PY2024 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097244000 Novo Nordisk Inc $21.81 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125017595 Abbott Laboratories $106.11 11/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125404955 Abbott Laboratories $806.00 03/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125404957 Abbott Laboratories $1,429.79 03/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125404959 Abbott Laboratories $335.61 03/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125404961 Abbott Laboratories $1,867.31 02/22/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125404963 Abbott Laboratories $192.09 02/22/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125404965 Abbott Laboratories $787.50 03/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1125404967 Abbott Laboratories $2,625.00 03/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1125404969 Abbott Laboratories $656.25 03/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1125404971 Abbott Laboratories $1,050.00 10/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1125404973 Abbott Laboratories $1,050.00 11/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1125404975 Abbott Laboratories $1,050.00 11/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1125404977 Abbott Laboratories $4,200.00 11/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1125404979 Abbott Laboratories $4,200.00 11/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1125404981 Abbott Laboratories $9.02 03/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.